

Mimics of Molar Pregnancy in Products of Conception Specimens

Ricardo R. Lastra, MD

Associate Professor

University of Chicago



Important Information Regarding CME

The **CME/evaluation** process will only be available on the USCAP website until **September 30, 2023**.

No claims can be processed after that date!

After **September 30, 2023** you will NOT be able to obtain any CME credits for attending this meeting.

Disclosure of Relevant Financial Relationships

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. USCAP has reviewed the disclosures and mitigated all relevant financial relationships.

The following faculty reported relevant financial relationships:

Ricardo R. Lastra, Consultant for ArsenalBio, Inc

USCAP staff associated with the development of content for this activity reported no relevant financial relationships.


Introduction

Hydatidiform moles

- Abnormal placental development
 - Hydropic villi
 - Excessive trophoblastic hyperplasia
- Excess paternal genome
- Divided into:
 - Complete hydatidiform mole
 - Partial hydatidiform mole
 - Invasive hydatidiform mole

Introduction

WHO 2019 Classification of Gestational Trophoblastic Diseases

Putative Trophoblastic Cell of Origin		Gestational Trophoblastic Disease Classification		Genetic Features
Chorionic villous trophoblast	Hydatidiform mole	Complete hydatidiform mole		Androgenetic paternal or inherited mutations (<i>NLRP7</i> or <i>KHDC3L</i>)
		Partial hydatidiform mole		Diandric monogynic triploidy
		Invasive hydatidiform mole		Dependent on prior mole
	 Atypical villous lesions			Unknown in most cases
Intermediate trophoblast	Villous IT	Gestational choriocarcinoma		Androgenetic XX following CHM
	Implantation site IT	Placental site trophoblastic tumor		Preferential requirement of paternal X chromosome
		Exaggerated implantation site		Unknown
	Chorionic-type IT	Epithelioid trophoblastic tumor		Preferential requirement of paternal X chromosome
		Placental site nodule/Atypical placental site nodule		Unknown
	Mixed IT	Mixed trophoblastic tumors		Unknown

Complete Hydatidiform Mole

- Hydatidiform mole without embryonic development
- Genetic etiology
 - Androgenetic diploidy
 - Diploid
 - Only paternal genetic material
 - Familial/inherited cases (uncommon)
 - Biparental diploid
 - Mutations in *NLRP7* or *KHDC3L* (abnormal expression of maternal germline)

Complete Hydatidiform Mole

Gross

- Bulky bloody tissue
- Vesicle formation
- Absent fetal parts
- If early - non-recognizable by gross evaluation




UNIV. OF CHICAGO
PATH.


METRIC 1 2 3 4 5 6 7 8 9 10


Complete Hydatidiform Mole

Histology

- Diffuse enlargement of villi
- Marked hydropic change/cisternae formation
- Prominent circumferential trophoblastic proliferation (often atypical)
- Hypercellular and myxoid villous stroma with karyorrhexis and abortive vessels
- No fetal parts
- Often associated exaggerated placental site







Partial Hydatidiform Mole

- Hydatidiform mole with a spectrum of villous morphology
- Villi range from normal to hydropic with mild trophoblastic hyperplasia
- Genetic etiology
 - Diandric triploid
 - Two set of chromosomes from father
 - One set of chromosomes from mother

Partial Hydatidiform Mole

Gross


- Gross evaluation
 - Difficult to recognize
 - Normal to mild hydropic change
 - Fetal parts or intact fetus present


Partial Hydatidiform Mole

Histology

Two separate villous populations

- Normal sized but fibrotic villi
- Enlarged villi with mild hydropic change
 - Mild trophoblastic hyperplasia
 - Peripheral scalloping
 - Trophoblastic pseudoinclusions
 - Fetal parts present (fetal structures or nucleated RBCs)





Hydatidiform Moles

Clinical Consequences

Complete hydatidiform mole

- Persistent GTD – 15-20%
- Choriocarcinoma – 2-3%
- Increased risk of subsequent CHM
- Follow β -hCG
- **Avoid pregnancy for 12 months**


Partial hydatidiform mole

- Persistent GTD – 0.5-5%
- Choriocarcinoma – <0.5%
- Follow β -hCG
- **Avoid pregnancy for 6 months**

**Problematic for women undergoing infertility treatment or
women with advanced maternal age**

Hydatidiform Moles

Diagnosis




Abnormal Villous Morphology

- Hydropic change

Abnormal Villous Morphology

Hydropic change




Abnormal Villous Morphology

- Hydropic change
- Unusual/peripheral trophoblastic hyperplasia

Abnormal Villous Morphology

Trophoblastic hyperplasia




Abnormal Villous Morphology

- Hydropic change
- Unusual/peripheral trophoblastic hyperplasia
- Peripheral scalloping and trophoblastic pseudoinclusions

Abnormal Villous Morphology

Scalloping and Pseudoinclusions




Abnormal Villous Morphology

- Hydropic change
- Unusual/peripheral trophoblastic hyperplasia
- Peripheral scalloping and trophoblastic pseudoinclusions
- Unusual stromal change (myxoid stroma, karyorrhectic debris, abortive vessels formation)

Abnormal Villous Morphology

Stromal Change




Abnormal Villous Morphology

- Hydropic change
- Unusual/peripheral trophoblastic hyperplasia
- Peripheral scalloping and trophoblastic pseudoinclusions
- Unusual stromal change (myxoid stroma, karyorrhectic debris, abortive vessels formation)
- Two distinct villous populations

Abnormal Villous Morphology

Dual villous population




Abnormal Villous Morphology

**Abnormal villous features in early hydatidiform moles
can be very subtle**

**Early CHM and PHM can have very similar
morphologic appearance**

Hydatidiform Moles

Diagnosis





p57 Immunohistochemistry

- p57 (*CDKN1C*) is located on chromosome 11p15.5
- Paternally imprinted, maternally expressed
- Normally expressed in villous stromal cells and cytotrophoblast
- Loss of p57 staining – lack of maternal DNA



Diagnosis of CHM

p57 Immunohistochemistry



p57 Loss in non-CHM

Positive/abnormal result → loss of expression

Must have appropriate
internal control

Tissue degeneration with
non-specific p57 IHC loss

Other alterations below
analytic resolution or in
non-targeted areas

Loss of p57 expression due
to isolated loss of 11p
(either PHM or non-molar
abortus)

Placental mesenchymal
dysplasia in Beckwith-
Wiedemann Syndrome


p57 Loss in non-CHM

In most cases, something does not add up

Lacking morphologic
features of CHM

Fetal parts present


Send for STR analysis to
definitively exclude CHM




Case 1

38-year-old patient with missed abortion at 10 weeks, undergoing dilation and curettage


Case 1



Case 1



Case 1



Case 1

Some abnormal villous morphology but not convincing for CHM



p57 essentially lost in cytotrophoblast and villous stromal cells
Decent internal control




STR analysis – balanced biparental diploid

NOT Complete hydatidiform mole


Case 2

22-year-old patient at 27 weeks gestation, undergoing vaginal delivery for IUFD. Pregnancy complicated by IUGR and ultrasonographic imaging concerning for partial hydatidiform mole versus large chorangioma. Cell-free DNA demonstrated normal karyotype.



Case 2



Case 2



Case 2



p57

Case 2

Abnormal villous architecture

Enlarged villi, prominent thick-walled vessels, dual villous population

Abnormal pattern of p57 expression (similar in both villous populations)

Fetus present with development until week 27 and normal cfDNA karyotype



Absence of classic CHM features (trophoblastic hyperplasia, stromal change)

Placental mesenchymal dysplasia



Case 3

25-year-old patient with missed abortion at 8 weeks, undergoing dilation and curettage

Case 3



Case 3




p57

Case 3

Two morphologically distinct villous populations




One of them with classic CHM morphologic features



p57 loss in the villi with CHM-like morphology, and retained in the second villous population (with nRBCs)

Twin pregnancy with complete hydatidiform mole component




UNIV. OF CHICAGO
PATH.

METRIC 1 2 3 4 5 6 7 8 9 10

Hydatidiform Moles



Diagnosis





Case 4

38-year-old patient with missed abortion at 10 weeks, undergoing dilation and curettage

Case 4



Case 4





p57

Case 5

29-year-old patient with missed abortion at 9 weeks, undergoing dilation and curettage

Case 5





p57

Case 6

27-year-old patient with missed abortion at 10 weeks, undergoing dilation and curettage

Case 6



p57

Hydatidiform Moles

Diagnosis – Chromosomal Analysis

Karyotyping

- Requires fresh tissue
- Labor intensive

FISH

- Probe against specific chromosome
- Diploid vs triploid
- False negatives
 - Nuclear truncation

Do not tell us where the
additional genetic material
is coming from



Cannot definitively
diagnose PHM

Hydatidiform Moles

Diagnosis – Molecular Testing (STR Analysis)


STR by PCR – compares:

- Mother DNA (from decidua)
- Fetal DNA (from chorionic villi)
- Comparison of STRs at various loci
 - Similar to identity testing

**GOLD STANDARD FOR DIAGNOSING
PHM**

Hydatidiform Moles


Diagnosis – Molecular Testing (STR Analysis)




Murphy, K. et al. Molecular Genotyping of Hydatidiform Moles. Analytic Validation of a Multiplex Short Tandem Repeat Assay. *J Mol Diagn.* 2009 Nov;11(6):598-605

Hydatidiform Moles

Diagnosis




Case 4




TRISOMY 21

Case 5




TRISOMY 16



p57

Case 6



p57

Conclusion

- Diagnosis of hydatidiform moles carries both clinical and emotional consequences
- In the right setting, loss of p57 by immunohistochemistry is usually sufficient to diagnose CHM
- Diagnosis of PHM required molecular testing for proper patient management

The background is a solid purple color with a network of thin, lighter purple lines connecting several large, semi-transparent purple circles of varying sizes. The circles are positioned in the corners and along the edges, creating a sense of a global or interconnected network.

THANK YOU!